Natural Disease Progression in Participants With Choroideremia
NCT ID: NCT04795206
Last Updated: 2021-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1178 participants
OBSERVATIONAL
2020-08-26
2021-08-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
NCT01977846
Color Vision as a Measure for Inherited Retinal Diseases
NCT01878032
Study of BEST1 Vitelliform Macular Dystrophy
NCT05809635
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
NCT05891275
Natural History Study of CEP290-Related Retinal Degeneration
NCT03396042
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Main Cohort
All eligible participants with CHM in IRIS Registry will be included.
No Intervention
Administered as specified in the treatment arm.
Cohort 2: Trial-Matched Cohort
Only male participants with CHM from Cohort 1 to match Biogen's IST study population using propensity score matching will be included.
No Intervention
Administered as specified in the treatment arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention
Administered as specified in the treatment arm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with a documented diagnosis of CHM identified by the presence of International Classification of Diseases (ICD)-9/10 or SNOMED coding:
1. ICD-9: 363.55
2. ICD-10: H31.2
3. SNOMED-CT: 75241009
Cohort 2: Trial-Matched CHM Participants
* Male participants with a documented diagnosis of CHM identified by the presence of ICD-9/10 or SNOMED coding:
1. ICD-9: 363.55
2. ICD-10: H31.21
3. SNOMED-CT: 75241009
Exclusion Criteria
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US-CHM-11761
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.